Corrigendum to “Continuation phase intravenous ketamine in adults with treatment-resistant depression” [J. Affect. Disord. 206 (2016) 300–304](S0165032716313519)(10.1016/j.jad.2016.09.008);Continuation phase intravenous ketamine in adults with treatment-resistant depression

Journal of Affective Disorders

Volumn 206, Issue , 2016, Pages 300-304

  Vande Voort, Jennifer L ^a   Morgan, Robert J ^a   Kung, Simon ^a   Rasmussen, Keith G ^a   Rico, Jose ^a   Palmer, Brian A ^a   Schak, Kathryn M ^a   Tye, Susannah J ^a   Ritter, Matthew J ^a   Frye, Mark A ^a   Bobo, William V ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bipolar depression; Continuation; Depression; Ketamine; Major depression; Repeated; Treatment resistant

Indexed keywords

KETAMINE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL OUTCOME; DISSOCIATIVE DISORDER; DIZZINESS; DSM-IV-TR; EMOTIONAL DISORDER; FACE DISORDER; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OPEN STUDY; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT HEALTH QUESTIONNAIRE 9; PRIORITY JOURNAL; SOMNOLENCE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUICIDAL IDEATION; TREATMENT FAILURE; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; REMISSION; SAMPLE SIZE; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; REMISSION INDUCTION; SAMPLE SIZE; SUICIDAL IDEATION; YOUNG ADULT;

EID: 84987940053     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2017.09.024     Document Type: Erratum

References (22)

1. aan het Rot, M., Collins, K.A., Murrough, J.W., Perez, A.M., Reich, D.L., Charney, D.S., Mathew, S.J., Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 67:2 (2010), 139–145.
2. Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., Krystal, J.H., Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47:4 (2000), 351–354.
3. Bobo, W.V., Vande Voort, J.L., Croarkin, P.E., Leung, J.G., Tye, S.J., Frye, M.A., Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depression Anxiety, 2016, 2016, 10.1002/da.22505.
4. Coyle, C.M., Laws, K.R., The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum. Psychopharmacol. 30:3 (2015), 152–163.
5. Diazgranados, N., Ibrahim, L., Brutsche, N.E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W.A., Quezado, Z., Luckenbaugh, D.A., Salvadore, G., Machado-Vieira, R., Manji, H.K., Zarate, C.A. Jr., A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment resistant bipolar depression. Arch. Gen. Psychiatry 67:8 (2010), 793–802.
6. Frye, M.A., Blier, P., Tye, S.J., Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J. Clin. Psychopharmacol. 35:3 (2015), 334–336.
7. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology —Revised (DHEW Publ. No. ADM 76–338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, pp. 218–222.
8. Hawley, C.J., Gale, T.M., Sivakumaran, T., Hertfordshire Neuroscience Research group, Defining remission by cut off score on the MADRS: selecting the optimal value. J. Affect. Disord. 72:2 (2002), 177–184.
9. McGirr, A., Berlim, M.T., Bond, D.J., Fleck, M.P., Yatham, L.N., Lam, R.W., A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol. Med. 45:4 (2015), 693–704.
10. Montgomery, S.A., Åsberg, M., A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134:4 (1979), 382–389.
11. Murrough, J.W., Ketamine as a novel antidepressant: from synapse to behavior. Clin. Pharm. Ther. 91:2 (2012), 303–309.
12. Murrough, J.W., Perez, A.M., Pillemer, S., Stern, J., Parides, M.K., aan het Rot, M., Collins, K.A., Mathew, S.J., Charney, D.S., Iosifescu, D.V., Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment resistant major depression. Biol. Psychiatry 74:4 (2013), 250–256.
13. Newport, D.J., Carpenter, L.L., McDonald, W.M., Potash, J.B., Tohen, M., Nemeroff, C.B., APA Council of Research Task Force on Novel Biomarkers and Treatments, Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am. J. Psychiatry, 172, 2015, 950–966.
14. Niciu, M.J., Grunschel, B.D., Corlett, P.R., Pittenger, C., Bloch, M.H., Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J. Psychopharmacol. 27:7 (2013), 651–654.
15. Rasmussen, K.G., Lineberry, T.W., Galardy, C.W., Kung, S., Lapid, M.I., Palmer, B.A., Ritter, M.J., Schak, K.M., Sola, C.L., Hanson, A.J., Frye, M.A., Serial infusions of low-dose ketamine for major depression. J. Psychopharmacol. 27:5 (2013), 444–450.
16. Sackeim, H.A., The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry 62:Suppl 16 (2001), S1–S17.
17. Schak, K.M., Vande Voort, J.L., Johnson, E.K., Kung, S., Leung, J.G., Rasmussen, K.G., Palmer, B.A., Frye, M.A., Potential risks of poorly monitored ketamine use in depression treatment. Am. J. Psychiatry 173:3 (2016), 215–218.
18. Shiroma, P.R., Albott, C.S., Johns, B., Thuras, P., Wels, J., Lim, K.O., Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment resistant depression. Int. J. Neuropsychopharmacol. 17:11 (2014), 1805–1813.
19. Singh, J.B., Fedgchin, M., Daly, E.J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J.W., Sanacora, G., Shelton, R.C., Kurian, B., Winokur, A., Fava, M., Manji, H., Drevets, W.C., Van Nueten, L., A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am. J. Psychiatry 173:8 (2016), 816–826.
20. Williamson, D., Brown, E., Perlis, R.H., Ahl, J., Baker, R.W., Tohen, M., Clinical relevance of depressive symptom improvement in bipolar I depressed patients. J. Affect. Disord. 92:2–3 (2006), 261–266.
21. Zarate, C., Brutsche, N.E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C.A., Liberty, V., Luckenbaugh, D.A., Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 71:11 (2012), 939–946.
22. Zarate, C.A. Jr, Singh, J.B., Carlson, N.E., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., Charney, D.S., Manji, H.K., A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63:8 (2006), 856–864.